Published in Am Health Drug Benefits on January 01, 2013
The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med (2003) 7.28
Effect of New York State regulatory action on benzodiazepine prescribing and hip fracture rates. Ann Intern Med (2007) 2.27
Medicare part D's exclusion of benzodiazepines and fracture risk in nursing homes. Arch Intern Med (2010) 1.86
Medicare Part D and nursing home residents. J Am Geriatr Soc (2007) 1.74
The exclusion of benzodiazepine coverage in medicare: simple steps for avoiding a public health crisis. Psychiatr Serv (2005) 1.43
Status report on Medicare Part D enrollment in 2006: analysis of plan-specific market share and coverage. Health Aff (Millwood) (2006) 1.36
Through the looking glass: the politics of the Medicare Prescription Drug, Improvement, and Modernization Act. J Health Polit Policy Law (2007) 1.01
Access to cancer drugs in Medicare Part D: formulary placement and beneficiary cost sharing in 2006. Health Aff (Millwood) (2006) 1.01
The FEHBP as a model for a new Medicare program. Health Aff (Millwood) (1995) 1.00
Identifying widely covered drugs and drug coverage variation among Medicare part D formularies. JAMA (2007) 0.99
Benzodiazepine use and expenditures for Medicare beneficiaries and the implications of Medicare Part D exclusions. Psychiatr Serv (2008) 0.89
Is premium support the right medicine for Medicare? Health Aff (Millwood) (2000) 0.84
Angiotensin receptor blockers on the formularies of Medicare drug plans. J Gen Intern Med (2007) 0.83
An analysis of availability of Medicare+Choice, commercial HMO, and FEHBP plans in rural areas: implications for Medicare reform. Rural Policy Brief (2003) 0.78